Pharma

What’s New With Three Sustained-Release Drug Platforms - Eye on Innovation

What’s New with Three Sustained-Release Drug Platforms

By Michael Smolinsky | March 23, 2016

Most ophthalmic drugs are delivered by topical application or direct injection into the vitreous, and many are limited by difficulties in sustaining therapeutic drug levels…

Read More
Mixed Topline Results Don’t Sidetrack Rhopressa Plans - Eye on Innovation

Mixed Results Don’t Sidetrack Rhopressa Plans

By Rich Kirkner | March 16, 2016

Despite tepid investor response to safety data from the latest comparative trial of its lead-candidate glaucoma agent, Aerie Pharmaceuticals says it is still on track…

Read More
OIS@ASCRS Award Winners

The OIS Lifetime Innovator Award goes to…

By Tom Salemi | March 15, 2016

Roger Steinert, MD     For A Lifetime of Exceptional Contributions to Ophthalmic Innovation and Entrepreneurship Dr. Steinert’s advanced skill and excellent surgical results have…

Read More
Highlights from AGS: New Surgical Devices, Novel Therapeutics - Eye on Innovation

Highlights from AGS: New Surgical Devices, Novel Therapeutics

By Michelle Dalton | March 9, 2016

This year’s American Glaucoma Society annual meeting feted novel medications designed to lower intraocular pressure (IOP) in patients with glaucoma. To date, available medications and…

Read More
How MIGS is Remaking the Glaucoma Market - Ophthalmology Innovation Summit 2015

How MIGS is Remaking the Glaucoma Market

By Larry Haimovitch | February 19, 2016

Glaucoma is a chronic degenerative disease whose incidence increases significantly with age. According to the World Health Organization, it is the second leading cause of…

Read More
Drugs & Devices for Dry Eye - Ophthalmology Innovation Summit 2015

2016 Promises to Disrupt Dry Eye

By Michelle Dalton | February 16, 2016

This year promises to deliver disruption to the dry eye disease market as companies work to roll out new drugs, devices, and diagnostics. Shire may…

Read More
Putting Brakes on IPO, Apellis Lines Up Private Funding - Eye on Innovation

Apellis IPO Road Show Takes Different Route

By Rich Kirkner | February 16, 2016

Putting Brakes on IPO, Apellis Lines Up Private Funding As the stock market took its 2016 nosedive, geographic atrophy drug developer Apellis Pharmaceuticals joined the…

Read More
Avalanche’s Post-AMD Pivot Takes Step Outside Ophthalmology - OIS Article

Avalanche’s Post-AMD Pivot Takes Step Outside Ophthalmology

By Rich Kirkner | February 10, 2016

How far will Avalanche Biotechnologies Inc.’s pivot take it outside of ophthalmology? Following the release of disappointing topline results of its lead gene therapy candidate…

Read More
OIS@AAO - Breakfast with the FDA

FDA Looking to Follow Up on Year of “Firsts”

By OIS Contributor | February 4, 2016

If you’re an executive at an ophthalmic drug development company and desire a frank discussion on regulatory issues that are critical to your business, you’d…

Read More
OIS@AAO - Combination Therapies for Wet AMD & DME

Exploring the Keys to Combination Therapies in Retina

By Rich Kirkner | February 3, 2016

The keys to developing combination therapies to treat retinal diseases lie in clinicians being able to better identify biomarkers for disease progression, developing strategies for…

Read More
Taking in the View of 2015 & Beyond

Taking in the View of 2015 & Beyond

By Tom Salemi | December 17, 2015

This year’s Ophthalmology Innovation Summits are behind us. We’re piling content onto OIS.NET including the 2015 Year in Review by OIS Founder and Co-Chair Emmett…

Read More
Next Few Months Important for Clearside

Next Few Months Important for Clearside

By Rich Kirkner | December 9, 2015

The next few months will be important for Clearside Biomedical, one of the companies pioneering drug delivery to the suprachoroidal space. The company expects by…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.